Novo Nordisk's Pediatric Obesity Drug Trial Shows Promise, But Commercial Success Uncertain
Novo Nordisk (NVO) has reported strong results from its late-stage STEP Young trial for semaglutide in treating pediatric obesity. The drug reduced BMI significantly compared to a placebo and led to 40.4% of children no longer being classified as obese after 68 weeks, assuming adherence. These findings could expand the market for Wegovy into younger age groups, but commercial success depends on regulatory approval and adoption by physicians and parents. The results come at a critical time for Novo Nordisk, which is trying to regain its position in the obesity drug market following mixed outcomes with its next-generation candidate CagriSema. While demand signals are strong—GLP-1 prescriptions among children aged 8–11 increased over 300-fold from 2019 to 2026—the company must still navigate regulatory hurdles and reimbursement challenges. Investor sentiment remains divided, with some hedge funds increasing their stakes while others have reduced holdings. The STEP Young trial offers a new growth avenue but does not guarantee revenue unless the drug gains approval and widespread adoption.
Tickers: $NVO
Topics: clinical trial results pediatric obesity semaglutide Wegovy